Association of anti-IL-12/23 biologic agents ustekinumab and briakinumab with major adverse cardiovascular events

J Eur Acad Dermatol Venereol. 2013 Dec;27(12):1586-7. doi: 10.1111/jdv.12126. Epub 2013 Mar 6.

Authors

T Tzellos¹, A Kyrgidis, A Trigoni, C C Zouboulis

Affiliation

¹ Division of Evidenced-Based Dermatology, Departments of Dermatology, Venereology, Allergology and Immunology, Dessau Medical Center, Dessau, Germany; Department of Pharmacology and Clinical Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.

PMID: 23461311
DOI: 10.1111/jdv.12126

No abstract available

Publication types

Letter
Comment

MeSH terms

Antibodies, Monoclonal / adverse effects*
Antibodies, Monoclonal / therapeutic use*
Female
Humans
Male
Psoriasis / drug therapy*

Substances

Antibodies, Monoclonal